Shopping Cart is Empty..

$ 0

Oct 2017 | 122 Views

Hospital Acquired Urinary Tract Infection Market by Product (Microbial Testing Instruments, Reagents and Consumables, Infection Prevention, and Surveillance Software), by Application (Disease Testing and Drug-resistance Testing), by Technology (Phenotypic Methods and Genotypic Methods), by Disease (Hospital acquired Pneumonia, Bloodstream infections, Surgical site infections, Gastrointestinal Infections, and Urinary Tract infections (UTI), and Others), and by End User (Hospitals and Intensive Care Units (ICUs), Ambulatory Surgical and Diagnostic Centers, Nursing Homes and Maternity Centers, and Others) - Global Opportunity Analysis and Industry and Forecast, 2017-2023

Diagnostics and Biotech	LI 173686	Pages: NA	Formats*:
Oct 2017 \| 122 Views	Charts: NA	Tables: NA	Author(s): NA

Hospital acquired urinary tract infections are caused by patients urethral catheters or invasive manipulation in the urogenital tract, which allows microbes to enter into the bladder and encourages proliferation by providing a sustainable environment. Hospital acquired UTIs are accountable for over 50% of infections. An array of tests can uncover type of infection and pathogen associated with the infection to efficiently treat the infected area.

Increase in prevalence of hospital acquired UTIs and technological advancement in testing devices drive the market. Moreover, favorable reimbursement scenario and focused disease management boost the market growth. However, strict regulatory policies and introduction of new testing devices into the market restrict the growth. Surge in preference over substitute products such as anti-infection catheters impedes the market growth.

The global hospital acquired urinary tract infection market is segmented on the basis of product, application, technology, disease, end user, and geography. On the basis of product, the market is divided into microbial testing instruments, reagents and consumables, infection prevention, and surveillance software. The microbial testing instruments are further divided into automated microbial identification systems, polymerase chain reaction (PCR) instruments, mass spectrometers, microarrays, polystainers, flow cytometers, and others. By application, the market is classified into disease testing, drug-resistance testing. On the basis of technology, the market is divided into phenotypic methods (phage-based assays, colorimetric methods, and nitrate reductase assay) and genotypic methods (DNA sequencing, solid-phase hybridization techniques, polymerase chain reaction techniques, microarrays). By diseases, the market is categorized into hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal infections, urinary tract infections (UTI), and others. By end user, the market is segmented into hospitals and intensive care units (ICUs), ambulatory surgical and diagnostic centers, nursing homes and maternity centers, and others. By geography, it is analyzed across North America, Europe, Asia Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Advanced Sterilization Products (Division Ethicon Us, LLC), Becton, Dickinson and Company, Steris Corporation, Getinge Group, Kimberly-Clark Corporation, Cantel Medical, Biomerieux SA, Belimed AG, 3M Company, Sterigenics International LLC., Synergy Health, and PLC are provided in this report.

Key Benefits

The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.
Extensive analysis of the market is conducted by following key product positioning and monitoring the top competitors within the market framework
It offers a quantitative analysis from 2017 to 2023 to enable the stakeholders to capitalize on the prevailing market opportunities.
Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

Hospital Acquired Urinary Tract Infection Market Key Segments:

By Product

Microbial Testing Instruments
- Automated Microbial Identification Systems
- Polymerase Chain Reaction (PCR) Instruments
- Mass Spectrometers
- Microarrays
- Polystainers
- Flow Cytometers
- Others
Reagents and Consumables
Infection Prevention and Surveillance Software

By Application

Disease Testing
Drug-resistance Testing

By Technology

Phenotypic Methods
- Phage-Based Assays
- Colorimetric Methods
- Nitrate Reductase Assay
Genotypic Methods
- DNA Sequencing
- Solid-Phase Hybridization Techniques
- Polymerase Chain Reaction Techniques
- Microarrays

By Disease

Hospital acquired Pneumonia
Bloodstream infections
Surgical site infections
Gastrointestinal Infections
Urinary Tract infections (UTI)
Others

By End User

Hospitals and Intensive Care Units (ICUs)
Ambulatory Surgical and Diagnostic Centers
Nursing Homes and Maternity Centers
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Taiwan
- Rest of Asia-Pacific
LAMEA
- Brazil
- Turkey
- Saudi Arabia
- South Africa
- Rest of LAMEA

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

License Type

Data Pack

Single User PDF

Five User Online/PDF

Enterprise Online/PDF

LICENSE INFO

Users/Sharing

Restricted to one authorized user

Limited to 5 authorized users

Unlimited within company / enterprise

Printing

One Print only

Up to Five Copies

Unlimited within company / enterprise

Delivery Formats

ADDED BENIFITS

20% Free customization (Pre-sale)

16 Analyst hour support (Post Sale)

40 Analyst hour support (Post Sale)

160 hours of mini-consult

Free quarterly industry update

Free report on update (within 180 days)

MULTIPLE PURCHASE

Complimentary report with 2 reports

Complimentary report with 3 reports

Subscription Model

Have questions ?
Speak with analyst

Did you miss anything?
To add more

* Taxes/Fees, If applicable, will be
added at the checkout. All prices in USD.

Need More Information

+1-503-894-6022

help@alliedmarketresearch.com

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to eliminate redundant information to provide valued information and save time of the reader

Get fresh content delivered

Get insights on topics that matter to your business. Stay updated on the areas that interest you.

Report Title: Hospital Acquired Urinary Tract Infection Market by Product (Microbial Testing Instruments, Reagents and Consumables, Infection Prevention, and Surveillance Software), by Application (Disease Testing and Drug-resistance Testing), by Technology (Phenotypic Methods and Genotypic Methods), by Disease (Hospital acquired Pneumonia, Bloodstream infections, Surgical site infections, Gastrointestinal Infections, and Urinary Tract infections (UTI), and Others), and by End User (Hospitals and Intensive Care Units (ICUs), Ambulatory Surgical and Diagnostic Centers, Nursing Homes and Maternity Centers, and Others) - Global Opportunity Analysis and Industry and Forecast, 2017-2023

Full Name: *:

Company Name: *:

Job Role: *:

Email: *:

Country: *:

Contact Number: *:

How can we help? *:

Security Code: *:

STAY WITH US

WE ACCEPT

* Pricing on the website is provided for single users licenses only. All reports will be provided in a PDF format for download. To purchase multi-user licenses, please contact us at +1-800-792-5285 or send an email to sales@alliedmarketresearch.com
Chapter: 1 INTRODUCTION 1.1. REPORT DESCRIPTION 1.2. KEY BENEFITS 1.3. KEY MARKET SEGMENTS 1.4. RESEARCH METHODOLOGY 1.4.1. Secondary research 1.4.2. Primary research 1.4.3. Analyst tools & models
Chapter: 2 EXECUTIVE SUMMARY 2.1. CXO PERSPECTIVE
Chapter: 3 MARKET OVERVIEW 3.1. MARKET DEFINITION AND SCOPE 3.2. KEY FINDINGS 3.2.1. Top investment pockets 3.2.2. Top winning strategies 3.3. MARKET SHARE ANALYSIS, 2016 3.4. PORTER’S FIVE FORCES ANALYSIS 3.4.1. MARKET DYNAMICS 3.4.2. Drivers 3.4.3. Restraints 3.4.4. Opportunities
Chapter: 4 HOSPITAL ACQUIRED URINARY TRACT INFECTION MARKET, BY PRODUCT 4.1. OVERVIEW 4.1.1. Market size and forecast 4.2. MICROBIAL TESTING INSTRUMENTS 4.2.1. Key market trends 4.2.2. Growth factors and opportunities 4.2.3. Market size and forecast 4.2.4. Automated Microbial Identification Systems 4.2.5. Polymerase Chain Reaction (PCR) Instruments 4.2.6. Mass Spectrometers 4.2.7. Microarrays 4.2.8. Polystainers 4.2.9. Flow Cytometers 4.2.10. Others 4.3. REAGENTS AND CONSUMABLES 4.3.1. Key market trends 4.3.2. Growth factors and opportunities 4.3.3. Market size and forecast 4.4. INFECTION PREVENTION AND SURVEILLANCE SOFTWARE 4.4.1. Key market trends 4.4.2. Growth factors and opportunities 4.4.3. Market size and forecast
Chapter: 5 HOSPITAL ACQUIRED URINARY TRACT INFECTION MARKET, BY APPLICATION 5.1. OVERVIEW 5.1.1. Market size and forecast 5.2. DISEASE TESTING 5.2.1. Market size and forecast 5.3. DRUG-RESISTANCE TESTING 5.3.1. Market size and forecast
Chapter: 6 HOSPITAL ACQUIRED URINARY TRACT INFECTION MARKET, BY TECHNOLOGY 6.1. OVERVIEW 6.1.1. Market size and forecast 6.2. PHENOTYPIC METHODS 6.2.1. Market size and forecast 6.2.2. Phage-based Assays 6.2.3. Colorimetric Methods 6.2.4. Nitrate Reductase Assay 6.3. GENOTYPIC METHODS 6.3.1. Market size and forecast 6.3.2. DNA Sequencing 6.3.3. Solid-phase Hybridization Techniques 6.3.4. Polymerase Chain Reaction Techniques 6.3.5. Microarrays
Chapter: 7 HOSPITAL ACQUIRED URINARY TRACT INFECTION MARKET, BY DISEASE 7.1. OVERVIEW 7.1.1. Market size and forecast 7.2. HOSPITAL ACQUIRED PNEUMONIA 7.2.1. Market size and forecast 7.3. BLOODSTREAM INFECTIONS 7.3.1. Market size and forecast 7.4. SURGICAL SITE INFECTIONS 7.4.1. Market size and forecast 7.5. GASTROINTESTINAL INFECTIONS 7.5.1. Market size and forecast 7.6. URINARY TRACT INFECTIONS (UTI) 7.6.1. Market size and forecast 7.7. OTHERS 7.7.1. Market size and forecast
Chapter: 8 HOSPITAL ACQUIRED URINARY TRACT INFECTION MARKET, BY END USER 8.1. OVERVIEW 8.1.1. Market size and forecast 8.2. HOSPITALS AND INTENSIVE CARE UNITS (ICUS) 8.2.1. Market size and forecast 8.3. AMBULATORY SURGICAL AND DIAGNOSTIC CENTERS 8.3.1. Market size and forecast 8.4. NURSING HOMES AND MATERNITY CENTERS 8.4.1. Market size and forecast 8.5. OTHERS 8.5.1. Market size and forecast
Chapter: 9 HOSPITAL ACQUIRED URINARY TRACT INFECTION MARKET, BY GEOGRAPHY 9.1. OVERVIEW 9.2. NORTH AMERICA 9.2.1. Key market trends 9.2.2. Key growth factors and opportunities 9.2.3. Market size and forecast 9.2.3.1. U.S. market size and forecast 9.2.3.2. Canada market size and forecast 9.2.3.3. Mexico market size and forecast 9.3. EUROPE 9.3.1. Key market trends 9.3.2. Key growth factors and opportunities 9.3.3. Market size and forecast 9.3.3.1. Germany market size and forecast 9.3.3.2. France market size and forecast 9.3.3.3. UK market size and forecast 9.3.3.4. Italy market size and forecast 9.3.3.5. Spain market size and forecast 9.3.3.6. Rest of Europe market size and forecast 9.4. ASIA-PACIFIC 9.4.1. Key market trends 9.4.2. Key growth factors and opportunities 9.4.3. Market size and forecast 9.4.3.1. Japan market size and forecast 9.4.3.2. China market size and forecast 9.4.3.3. Australia market size and forecast 9.4.3.4. India market size and forecast 9.4.3.5. South Korea market size and forecast 9.4.3.6. Taiwan market size and forecast 9.4.3.7. Rest of Asia-Pacific market size and forecast 9.5. LAMEA 9.5.1. Key market trends 9.5.2. Key growth factors and opportunities 9.5.3. Market size and forecast 9.5.3.1. Brazil market size and forecast 9.5.3.2. Turkey market size and forecast 9.5.3.3. Saudi Arabia market size and forecast 9.5.3.4. South Africa market size and forecast 9.5.3.5. Rest of LAMEA market size and forecast
Chapter: 10 COMPANY PROFILES 10.1. ADVANCED STERILIZATION PRODUCTS (DIVISION ETHICON US, LLC) 10.1.1. Operating business segments 10.1.2. Business performance 10.1.3. Key strategic moves and developments 10.2. BECTON, DICKINSON AND COMPANY 10.2.1. Operating business segments 10.2.2. Business performance 10.2.3. Key strategic moves and developments 10.3. STERIS CORPORATION 10.3.1. Operating business segments 10.3.2. Business performance 10.3.3. Key strategic moves and developments 10.4. GETINGE GROUP 10.4.1. Operating business segments 10.4.2. Business performance 10.4.3. Key strategic moves and developments 10.5. KIMBERLY-CLARK CORPORATION 10.5.1. Operating business segments 10.5.2. Business performance 10.5.3. Key strategic moves and developments 10.6. CANTEL MEDICAL, BIOMERIEUX SA 10.6.1. Operating business segments 10.6.2. Business performance 10.6.3. Key strategic moves and developments 10.7. BELIMED AG 10.7.1. Operating business segments 10.7.2. Business performance 10.7.3. Key strategic moves and developments 10.8. 3M COMPANY 10.8.1. Operating business segments 10.8.2. Business performance 10.8.3. Key strategic moves and developments 10.9. STERIGENICS INTERNATIONAL LLC 10.9.1. Operating business segments 10.9.2. Business performance 10.9.3. Key strategic moves and developments 10.10 SYNERGY HEALTH, AND PLC 10.10.1 Operating business segments 10.10.2 Business performance 10.10.3 Key strategic moves and developments

Purchase Options